



Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

Stefania Lombardi^{1*}, Cristina Bernardoni⁶, Daniela Bertolucci², Riccardo Cecchetti³, Francesca De Giorgio⁴, GianLuigi Occhipinti⁵, Andrea Palagi¹, Gloria Bertacca¹, Isabella Giannelli¹, Elena Bonomi¹, Marco Friggeri¹ and Giancarlo Tartarelli⁶

*Correspondence: stefania.lombardi@uslnordovest.toscana.it



CrossMark

← Click for updates

¹SSD Clinical Analysis and Immunoallergology, Massa Carrara, Italy.

²Center for Rheumatology, Versilia, Italy.

³Center for Rheumatology, Pontedera, Italy.

⁴Center for Rheumatology, Pistoia, Italy.

⁵Center for Rheumatology, Livorno, Italy.

⁶SSD Rheumatology Massa Carrara, Italy.

Abstract

Background: The aim of this study was to evaluate the relevance of drug and anti-drug antibody detection in the clinical management of patients with rheumatoid arthritis (RA) and spondyloarthropathies (SpA) in treatment with anti-tumor necrosis factor alpha (TNF α) biologics.

Methods and results: The study included 192 adult consecutive patients treated for at least 6 months with adalimumab (ADA) or etanercept (ETN) or infliximab (IFX); patients underwent clinical observations in the Rheumatologic Unit of 5 Hospitals in Tuscany. Their demographic and clinical characteristics to calculate DAS28 and BASDAI scores were collected. Drug levels and anti-drug antibodies (anti-drug Ab) were evaluated immediately before drug injection or infusion. A total of 192 patients were studied: 62 receiving IFX, 64 ADA, and 66 ETN with a mean age of 57 years (range 18-86 years); the study group was composed of 51% women. Forty percent of the patients were affected by RA, 60% by SpA. Altogether, 81% of patients demonstrated therapeutic drug levels. Anti-drug Ab were found in 19% of patients taking IFX, 10% taking ETN and 5% taking ADA. No significant correlation was found between anti-drug Ab presence and low drug levels, between anti-drug Ab and high DAS28 and BASDAI scores, as well as between low drug levels and high DAS28 and BASDAI scores.

Conclusions: Low drug levels were found in 19% of the rheumatic patients and there were not correlations with presence of anti-drug Ab or patient's clinical status.

Keywords: Anti-tumor necrosis factor alpha (TNF α) biologics, anti drug antibodies, rheumatoid arthritis, spondyloarthropathies, drug levels

Introduction

ADA, ETN and IFX, all TNF α blockers, actually represent an important therapeutic aid for RA and SpA patients. In a third of cases such drugs are ineffective and this is due to primary treatment failure (drug inefficacy or serious side effects) or secondary treatment failure (drug loss of efficacy after initial good response). It has been shown that serum levels of ADA, ETN and IFX correlate with the clinical response in RA, while in ankylosing spondylitis (AS) data are controversial [1-4]. Similarly, anti-drug Ab levels inversely correlate with drug levels and therapeutic response [4-6]. The mechanism of drug inactivation is linked to anti-drug Ab formation (against biological medications) which causes the neutralization of the

drug and its increased clearance [5]: only 4% of patients with anti-adalimumab antibodies (anti-ADA Ab) achieved clinical remission compared to 34% anti-ADA Ab negative patients [6]. ETN has shown a less immunogenic effect with anti-etanercept antibodies (anti-ETN Ab) not detectable or present only in a low number of patients; as a consequence anti-ETN immune response has a minimal effect on clinical response [4,7-9]. A clinically relevant impact of anti-drug Ab is described in about half of the patients receiving repeated TNF α monotherapy and therefore immune suppression by concomitant administration of methotrexate (MTX) is indicated in RA and SpA patients [8,10-21]. Detectable anti-drug Ab decrease TNF α blockers response by as much as 80% [22]. This has been shown with only one

or two biologic treatments without comparing differences in patients suffering from different inflammatory diseases.

The aims of our study were: a) to assess the relationship between clinical response and TNF α blockers serum levels and anti-drug Ab concentrations in RA and SpA (AS and psoriatic arthritis (PsA)) patients treated with ADA, ETN, and IFX b) to verify if a single serological determination could be useful in clinical practice for patient management.

Methods

Study population

Between September 2014 and February 2015, consecutive patients with RA and SpA, that were treated with anti-TNF α biologics were invited to participate to the present study. Patients were followed by the Rheumatology Units of 5 Tuscany hospitals participating in the study. The study included 192 adults ≥ 18 years who were treated with either ADA, IFX or ETN monotherapy or concomitant MTX therapy. Exclusion criteria were: patients treated with a different TNF α blocker or for less than 6 months. Written consent was obtained from all participants and the study was approved by the Ethics Committee of our hospital. Clinical data and blood samples were collected from patients just before they received a new intravenous or subcutaneous dose of the anti-TNF α agents. Samples were kept a -20°C until processed.

Assessment of disease activity

RA disease activity was assessed using the 28-joint disease activity score (DAS28) (swollen joint count, tender joint count, ESR and general health) as described elsewhere [23]. The disease activity of SpA was assessed using the Bath ankylosing spondylitis disease activity index (BASDAI) on a 100-mm visual analogue scale as previously described [24].

Definition of clinical response

The clinical response to anti-TNF α treatment in RA patients was assessed using the EULAR response criteria [25]. Briefly, the criteria were: adequate response $\text{DAS28} \leq 3.2$; moderate response $\text{DAS28} \leq 5.1$; non adequate response $\text{DAS28} > 5.1$. For patients with SpA the criteria were: adequate response $\text{BASDAI} \leq 2$; moderate response $\text{BASDAI} \leq 4$; non adequate response $\text{BASDAI} > 4$.

Dosage of the anti-TNF α agents

The dosage of IFX was 3 mg/Kg per dose for RA and 5 mg/Kg for SpA, given as intravenous infusion at baseline, week 2, 6, and then every 6-8 weeks. ETN was given subcutaneously at 50 mg per dose every week. ADA was given subcutaneously at 40 mg per dose every 2 weeks.

Drug concentration and anti-drug antibody assays

Serum drug levels and anti-drug Abs were evaluated immediately before next drug injection or infusion. Concentrations of free IFX and ADA were measured in serum samples

by IDK monitor Infliximab or Adalimumab drug level ELISA, respectively, according to the manufacturer's instructions (Immunodiagnostik AG, Bensheim, Germany). Concentrations of serum free ETN were measured by Shikari Q-ETA (Matriks Biotek Laboratories, Israel). Briefly, standards and serum samples were incubated in the microtitre plate coated with the specific monoclonal anti-IFX or ADA or ETN antibody. Following incubation wells were washed and peroxidase-labeled anti-IFX or ADA or ETN specific antibody was added. After incubation, wells were washed and the bound enzymatic activity was detected by addition of chromogenic substrate. A dose response curve, specific for each biologic, was generated using the values obtained from standards. The concentrations of free biologic in the samples were determined directly from the curve. Results were expressed as ng/ml for ADA and IFX and as $\mu\text{g/ml}$ for ETN. The ELISA detection limits were: 2.3 ng/ml and 2.6 ng/ml for IFX and ADA assays respectively, and 0.2 $\mu\text{g/ml}$ for ETN assay. No cross reactivity to other plasma proteins or anti TNF α -blockers, different from the investigated one, was reported.

The presence in serum samples of free human antibodies against IFX, ADA and ETN was detected by IDK monitor Infliximab or Adalimumab total ADA ELISA and IDK monitor Etanercept free ADA ELISA, respectively (Immunodiagnostik AG, Bensheim, Germany). Briefly, in the first incubation step the free anti-drug antibodies from the sample were bound to the drug coated on the plate. To remove all unbound substances, a washing step was carried out. In a further incubation step, peroxidase-labeled therapy antibody was added. After another washing step, to remove all unbound substances, the solid phase was incubated with chromogenic substrate. The optical density was directly proportional to the amount of bound anti-drug Ab from sample. Results were evaluated by a cut-off control. Samples with optical density higher than that of the specific drug cut off were considered positive.

Statistical analysis

Unless otherwise indicated, values were expressed as mean \pm standard deviation. Comparison of continuous variables between two groups was performed by the non-parametric Mann-Whitney rank sum test. Discrete variables were compared, by group, using chi square test. When the frequency was < 5 , the Fisher's exact test was used. Statistical significance was defined as a two-tailed p value of < 0.05 .

Results

Characteristics of the study population

The study enrolled a total of 192 patients of which 51% were women. The mean age at the time of blood collection was 60 ± 12 years for women and 55 ± 13 years for men.

The underlying diseases of these patients that warranted anti-TNF α treatment were: RA (N=77; 40%) and SpA (N=115; 60%). The proportion of patients treated with IFX, ADA and ETN, was 32% (N=62), 33% (N=64) and 35% (N=66), respectively.

The mean duration of therapy at the time of blood collection was 56±35, 42±36 and 57±39 months for IFX, ADA and ETN users, respectively.

Table 1 shows the gender and age distribution of the studied patients. As shown, male subjects are predominant in the 18-45 age group, representing 66.7% of the patients, while an opposite figure is found in the >67 age group where women represent 60.9% of the patients. No difference in gender distribution is observed in the 46-66 age group. Subdividing the 18-45 and >67 age groups by gender and disease (**Table 2**), it was observed that in the 18-45 age group the prevalence of SpA is significantly higher (p=0.01) than RA in male patients, while in the >67 years group the prevalence of RA is lightly higher (64.3%) in female patients. Taking into account gender and disease distribution of the 192 patients, women represent 64.9% (50 out 77) of RA patients with a 1.9:1 female/male ratio.

Drug and anti-drug antibody in RA and SpA patients

The relationship between serum drug levels and anti-drug Ab presence for each drug treatment was evaluated in both RA and SpA patients (**Table 3**). Antibodies against IFX were demonstrated in 12 (19.4%) patients, 5 RA and 7 SpA patients; anti-ADA Ab were detected only in 3 (4.7%) patients all belonging to the RA group; anti-ETN Ab were present in 6 (9%) patients, 4 RA and 2 SpA. As shown in **Table 3**, patients who developed anti-drug Ab don't had drug levels significantly different from patients who did not developed anti-drug Ab.

Serum drug level, anti-drug Ab status and clinical response in RA and SpA patients

In order to analyze the relationship between serum drug levels and clinical response, RA and SpA patients were divided

Table 1. Patient gender distribution for age groups.

Age group	Patients			
	Female		Male	
	N°	Prevalence %	N°	Prevalence %
18-45 years	13	33.3	26	66.7
46-54 years	24	49.0	25	51.0
55-66 years	33	56.9	25	43.1
>67 years	28	60.9	18	39.1

Table 2. Disease distribution for gender.

Age group	Disease	Patients			
		Female		Male	
		N°	Prevalence %	N°	Prevalence %
18->67 years	RA	50	51	27	28.7
	SpA	48	49	67	71.3
18-45 years	RA	5	38.4	3	11.5
	SpA	8	61.6	23	88.5
46-54 years	RA	7	29.1	5	20
	SpA	17	70.9	20	80
55-66 years	RA	20	54.1	8	32
	SpA	13	41.9	17	68
>67 years	RA	18	64.3	11	61.1
	SpA	10	35.7	7	38.9

into three groups according to DAS28 and BASDAI scores, respectively. As shown in **Table 4**, there were no significant differences in serum drug levels between subjects of the three DAS28 and BASDAI categories both in RA and SpA patients. Moreover, for each drug treatment no significant difference was observed in the clinical response of anti-drug Ab positive and negative subjects in each disease group (**Table 5**).

Table 3. Relationship between serum drug levels and anti-drug Ab in between RA and SpA patients.

	INFLIXIMAB					
	RA patients (N.18)			SpA patients(N. 44)		
	Anti-IFX Ab Positive (N. 5)	Anti-IFX Ab Negative (N.13)	P-value	Anti-IFX Ab Positive (N. 7)	Anti-IFX Ab Negative (N. 37)	P-value
IFX serum concentration Mean±SD (ng/ml)	5.51±8.71	13.75±13.73	0.49	3.68±4.11	15.53±18.23	0.25
	ADALIMUMAB					
	RA patients (N.27)			SpA patients (N. 37)		
	Anti-ADA Ab Positive (N. 3)	Anti-ADA Ab Negative (N. 24)	P-value	Anti-ADA Ab Positive (N. 0)	Anti-ADA Ab Negative (N. 37)	P-value
ADA serum concentration Mean±SD (ng/ml)	18.19±30.64	40.87±60.11	0.73	--	40.65±30.51	--
	ETANERCEPT					
	RA patients (N.32)			SpA patients (N. 34)		
	Anti-ETN Ab Positive (N. 4)	Anti-ETN Ab Negative (N. 28)	P-value	Anti-ETN Ab Positive (N. 2)	Anti-ETN Ab Negative (N. 32)	P-value
ETN serum concentration Mean±SD (µg/ml)	2.71±1.69	3.89±0.58	0.43	4±0	3.55±0.98	0.50

Table 4. Relationship between serum drug levels and clinical efficacy in between RA and SpA patients.

INFLIXIMAB							
RA patients [N.18]				SpA patients [N.44]			
DAS28	Number of patients	Drug concentration Mean±SD (ng/ml)	P-value	BASDAI	Number of patients	Drug concentration Mean±SD (ng/ml)	P-value
≤3.2	8	9.95±11.33	0.69	≤2	15	10.77±11.06	0.43
≤5.1	7	7.64±8.34	0.63	≤4	21	13.08±11.72	0.36
>5.1	3	24.42±20.87	0.43	>4	8	20.73±33.60	0.61
ADALIMUMAB							
RA patients [N.27]				SpA patients [N.37]			
DAS28	Number of patients	Drug concentration Mean±SD (ng/ml)	P-value	BASDAI	Number of patients	Drug concentration Mean±SD (ng/ml)	P-value
≤3.2	15	42.49±55.37	0.29	≤2	22	46.31±29.12	0.13
≤5.1	11	36.13±64.56	0.15	≤4	9	32.09±21.86	0.13
>5.1	1	0.5	0.27	>4	6	57.42±43.38	0.35
ETANERCEPT							
RA patients [N.32]				SpA patients [N.34]			
DAS28	Number of patients	Drug concentration Mean±SD (µg/ml)	P-value	BASDAI	Number of patients	Drug concentration Mean±SD (µg/ml)	P-value
≤3.2	25	3.81±0.68	0.92	≤2	12	3.24±1.26	0.71
≤5.1	5	3.28±1.59	0.84	≤4	13	3.79±0.67	0.66
>5.1	2	4.0±0	0.95	>4	9	3.74±0.78	0.92

Table 5. Relationship between anti-drug Ab status and clinical efficacy in between RA and SpA patients.

INFLIXIMAB							
RA patients (N.18)				SpA patients (N.44)			
	Anti-IFX Ab Positive (N. 5)	Anti-IFX Ab Negative (N.13)	P-value	--	Anti-IFX Ab Positive (N. 7)	Anti-IFX Ab Negative (N. 37)	P-value
DAS28 Mean±SD	4.29±2.13	3.57±1.45	0.85	BASDAI Mean±SD	2.88±1.83	2.29±1.62	0.40
ADALIMUMAB							
RA patients (N.27)				SpA patients (N.37)			
	Anti-ADA Ab Positive (N. 3)	Anti-ADA Ab Negative (N.24)	P-value	--	Anti-ADA Ab Positive (N. 0)	Anti-ADA Ab Negative (N. 37)	P-value
DAS28 Mean±SD	4.54±2.07	3.10±1.03	0.63	BASDAI Mean±SD	--	2.62±3.07	--
ETANERCEPT							
RA patients (N.32)				SpA patients (N.34)			
	Ant-ETN Ab Positive (N. 4)	Ant-ETN Ab Negative (N.28)	P-value	--	Ant-ETN Ab Positive (N. 2)	Ant-ETN Ab Negative (N. 32)	P-value
DAS28 Mean±SD	2.72±1.03	2.88±1.10	0.57	BASDAI Mean±SD	1.95 ± 0.91	3.05±1.90	0.78

Serum drug level, anti-drug Ab status and clinical response in RA and SpA patients treated with anti-TNFα monotherapy or concomitant MTX therapy

In order to verify the effects of the concomitant use of MTX, RA and SpA patients were divided into MTX users and MTX non-users, and serum drug levels, anti-drug Ab status and clinical response were analyzed (Table 6). Data show that for each drug treatment there was no significant difference in serum drug level and clinical status between MTX users and MTX non-users. Moreover, anti-drug Ab positive subjects were present in both MTX groups with no significant difference; in SpA patients under IFX therapy, 26% of MTX non-users developed anti-drug Ab compared to 5.6% of MTX users but

the difference was not significant (p=0.11).

Discussion

TNF blockers represent a breakthrough in the management of rheumatic diseases, including RA and SpA, having a relevant effect on their clinical course and prognosis. These drugs, however, have some limitations due to primary or secondary loss of efficacy. The latter maybe determined by the phenomenon of immunogenicity [26,27] which lowers the blood levels of effective drug and consequently decreases the clinical response.

The aim of this study was to evaluate the relevance of drug and anti-drug antibody detection on the clinical management

Table 6. Relationship between MTX therapy and clinical efficacy, serum drug levels and anti-drug Ab status in between RA and SpA patients.

INFLIXIMAB											
RA patients						SpA patients					
N (%)	MTX mg/week median (range)	DAS28 Mean±SD	IFX serum concentration mean±SD ng/ml	N° Anti-IFX Ab positive patients	N (%)	MTX mg/week median (range)	BASDAI Mean±SD	IFX serum concentration mean±SD ng/ml	N° Anti-IFX Ab positive patients	N (%)	MTX mg/week median (range)
MTX users (78)	10 (7.5-15)	3.8±1.78	12.9±14.1	5	18 (41)	7.5 (5-15)	2.51±1.07	10.2±7.8	1		
MTX non users (22)	0	3.66±1.19	6.14±4.86	0	26 (59)	0	3.17±1.37	16.6±21.84	6		
ADALIMUMAB											
RA patients						SpA patients					
N (%)	MTX mg/week median (range)	DAS28 Mean±SD	ADA serum concentration mean±SD ng/ml	N° Anti-ADA Ab positive patients	N (%)	MTX mg/week median (range)	BASDAI mean±SD	ADA serum concentration mean±SD ng/ml	N° Anti-ADA Ab positive patients	N (%)	MTX mg/week median (range)
MTX users (78)	10 (7.5-20)	3.71±2.01	44.9±64.9	2	16 (43)	10 (7.5-15)	2.14±1.20	46.9±26.0	0		
MTX non users (22)	0	3.10±0.91	15.3±20.0	1	21 (57)	0	3.24±4.46	41.6±36.2	0		
ETANERCEPT											
RA patients						SpA patients					
N (%)	MTX mg/week median (range)	DAS28 Mean±SD	ETN serum concentration mean±SD µg/ml	N° Anti-ETN Ab positive patients	N (%)	MTX mg/week median (range)	BASDAI mean±SD	ETN serum concentration mean±SD µg/ml	N° Anti-ETN Ab positive patients	N (%)	MTX mg/week median (range)
MTX users (75)	10 (5-20)	2.79±1.05	3.65±0.98	3	11 (32)	10 (5-20)	3.4±1.82	3.43±1.18	1		
MTX non users (25)	0	2.56±0.87	4.0±0	1	23 (68)	0	2.78±2.0	3.65±0.84	1		

of RA and SpA patients treated with anti-TNFα biologics.

The study population included 192 patients of which 98 were females and 94 males. Fifty-two % of female population was affected by RA and 48% by SpA, while only 28.8% of male patients was RA; the incidence of RA, as expected [28], is higher

in the female population with a ratio female/male 2:1. When the population was subdivided in age groups, it was observed that in the intermediate age groups (46-54 and 55-66 years) the number of female and male patients was equivalent, while, in the 18-45 group, males were predominant with a prevalence

of 67% and in the ≥ 67 years females reached 61%. In the 18-45 group the SpA is the disease with the highest prevalence of 79.5%; in particular, in the male population SpA is significantly higher (74% $p=0.01$) than RA (26%) while in females the two diseases are roughly equivalent. Moreover the female:male ratio of patients affected by SpA is 1:3 in agreement with data from the literature that show a higher prevalence of SpA in young males with a ratio female:male of 1:3 [29]. In the ≥ 67 age group females and males are 60.9% and 39.1% respectively. In the female group RA shows a prevalence of 64.3% and SpA 35.7%. A higher prevalence of RA in females is reported in the literature: in women RA develops between 30- 50 years with an incidence 3-5 times higher in females than males and this incidence tends to decrease with increasing age [29]. Therefore our results demonstrate that the study population is epidemiologically representative of the two autoimmune diseases both for sex and for age distribution.

In the literature, the percentage of patients who develop anti-drug Ab may vary by sex, different autoimmune inflammatory diseases and among different anti-TNF treatments. In this study, patients with anti-drug Ab were 21/192 (10.9%), 8 females and 13 males (data not shown) indicating that there is no correlation between drug immunogenicity and sex of the patient in contrast with what it was described by Mok [5] who reported a higher prevalence of anti-drug Ab in females than in males.

Anti-drug Ab are generally reported as detected in up to one third of RA and about 25% of SpA patients [2,30-33]. Chimeric drugs (mouse-human), such as IFX, have a greater likelihood of inducing anti-drug Abs production compared to fully human antibodies [34,35]. Not all patients treated with anti-TNF therapy develop anti-drug Ab and this seems to be multi-factorial: the treatment, the patient, external factors [33]. We have found that the phenomenon of immunogenicity is present for all used drug treatments in RA patients while in SpA patients is limited to IFX and ETN. Anti-IFX Ab were present in 28% of RA and 16% of SpA patients in accordance with previous studies revealing anti-IFX Ab from 12 to 44% in RA [36] and from 6 to 61% in SpA [37]. Anti-ETN Ab were found in 12.5% of RA and 6% of SpA patients and anti-ADA Ab in 11% of RA patients; ETN is considered the less immunogenic one and only few studies [38] report the presence of anti-ETN Ab in SpA patients. In our hands, on the contrary, ADA is the treatment that shows the lowest rate of anti-drug Ab (4.7%) compared to IFX (19.4%) and ETN (9.0%).

We did not find statistically significant differences between serum TNF α blockers concentrations in RA and SpA patients that did and did not develop anti-drug Ab, although in previous studies low serum drug levels resulted inversely correlated with anti-drug Ab presence [5]. Moreover, no significant differences were found between drug levels and clinical status in RA and SpA classified by DAS28 or BADAIS score; furthermore, no significant difference was observed in the clinical response of anti-drug Ab positive and negative subjects of each

disease group. Most of the studies refer that therapy failure occurred more frequently in positive anti-drug Ab patients [3,32,37,39], although there are previous reports which did not find a similar relation [40-42]. It is also reported that the concomitant use of MTX with anti-TNF α drugs reduces the incidence of anti-drug Ab [6,36]; in our study, in agreement with opposite results [13,39] concomitant MTX therapy was irrelevant on anti-drug Ab development.

A possible explanation of the discrepancies observed in the present study could be found in the recruitment criteria of the patients population; the patients of this study represent a consecutive population in the normal daily clinical setting without selection based on the presence or absence of anti-drug Ab. Moreover, in order to simulate more precisely the normal clinical use of these diagnostic tools in real clinical practice it has been decided to collect blood only once.

It has been described that anti-TNF Ab titres can decrease and increase over time, and vice versa [37,43,44], causing a gradual increase in incidence over time when anti-drug Ab status is presented cumulatively, but not when assessed at each time point independently [44]. This explains why the time of measuring can influence the relevance and interpretation of anti-drug Ab status. It is therefore very difficult to draw a well-defined statement regarding the relationship between clinical response and anti-drug Ab measurement in clinical practice.

Conclusion

Our results indicate that the link between either serum drug levels or anti-drug Ab and clinical response is not as strong as previously assumed. This argues against the use of these parameters in monitoring drug efficacy. Although testing immunogenicity in clinical trials is standard practice and may yield interesting scientific insights, in clinical practice the real added value of the presence or absence of anti-drug Ab and the detection serum drug levels in an individual patient remains to be demonstrated.

Competing interests

The authors declare that they have no competing interests.

Acknowledgement and funding

This study was supported by an unconditioned research grant from Pfizer Inc.

Publication history

Editor: Pier Luigi Meroni, University of Milan, Italy.
Received: 03-Jan-2017 Final Revised: 13-Feb-2017
Accepted: 27-Mar-2017 Published: 11-Apr-2017

References

1. Kneepkens EL, Krieckaert CL, van der Kleij D, Nurmohamed MT, van der Horst-Bruinsma IE, Rispens T and Wolbink GJ. **Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.** *Ann Rheum Dis.* 2015; **74**:1825-9. | [Article](#) | [PubMed](#)

2. Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, van der Horst-Bruinsma IE, van der Kleij D, Rispiens T, Wolbink G and Kriekkaert CL. **Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up.** *Ann Rheum Dis.* 2015; **74**:396-401. | [Article](#) | [PubMed](#)
3. de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA and van der Horst-Bruinsma IE. **Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.** *Ann Rheum Dis.* 2007; **66**:133-4. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
4. Mazilu D, Opris D, Gainaru C, Iliuta M, Apetrei N, Luca G, Borangiu A, Gudu T, Peltea A, Groseanu L, Constantinescu C, Saulescu I, Bojinca V, Balanescu A, Predeteanu D and Ionescu R. **Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.** *Biomed Res Int.* 2014; **2014**:702701. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
5. Mok CC, van der Kleij D and Wolbink GJ. **Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases.** *Clin Rheumatol.* 2013; **32**:1429-35. | [Article](#) | [PubMed](#)
6. Bartelds G M, Kriekkaert C L M, Nurmohamed M T, van Schouwenburg PA and Lems WF. **Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm follow-up.** *The Journal of the American Medical Association.* 2011; **305**:1460-1468. | [Article](#)
7. Hoshino M, Yoshio T, Onishi S and Minota S. **Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis.** *Mod Rheumatol.* 2012; **22**:532-40. | [Article](#) | [PubMed](#)
8. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA and Wolbink GJ. **Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.** *Ann Rheum Dis.* 2009; **68**:531-5. | [Article](#) | [PubMed](#)
9. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L and Peloso P. **The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.** *Clin Exp Rheumatol.* 2007; **25**:40-6. | [Article](#) | [PubMed](#)
10. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L and Dijkmans B. **Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.** *Arthritis Rheum.* 2006; **54**:711-5. | [Article](#) | [PubMed](#)
11. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP and Heilig B. **Immunogenicity, efficacy and adverse events of adalimumab in RA patients.** *Rheumatol Int.* 2007; **27**:269-74. | [Article](#) | [PubMed](#)
12. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C and Finckh A. **Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.** *Arthritis Rheum.* 2009; **61**:560-8. | [Article](#) | [PubMed](#)
13. Perez-Guijo VC, Cravo AR, Castro Mdel C, Font P, Munoz-Gomariz E and Collantes-Estevez E. **Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis.** *Joint Bone Spine.* 2007; **74**:254-8. | [Article](#) | [PubMed](#)
14. Mulleman D, Lauferon F, Wendling D, Ternant D, Ducourau E, Paintaud G and Goupille P. **Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study.** *Arthritis Res Ther.* 2011; **13**:R82. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
15. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, Euller-Ziegler L, Pham T, Solau-Gervais E, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loet X, Wendling D, Fautrel B, Fournie B, Combe B, Gaudin P, Jousse S, Mariette X, Baleyrier A, Trape G and Dougados M. **Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment.** *Arthritis Rheum.* 2008; **58**:88-97. | [Article](#) | [PubMed](#)
16. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF and Samara AM. **Methotrexate in the treatment of ankylosing spondylitis.** *Scand J Rheumatol.* 2000; **29**:160-2. | [PubMed](#)
17. Maini R N, Breedveld F C, Kalden J R, Smolen JS and Davis D. **Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.** *Arthritis & Rheumatism.* 1998; **41**:1552-1563. | [Article](#)
18. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR and Maini RN. **Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.** *N Engl J Med.* 2000; **343**:1594-602. | [Article](#) | [PubMed](#)
19. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A and Keystone EC. **The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.** *Arthritis Rheum.* 2002; **46**:1451-9. | [Article](#) | [PubMed](#)
20. Arora A, Mahajan A, Spurdin D, Boyd H and Porter D. **Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers.** *Int J Rheumatol.* 2013; **2013**:764518. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
21. Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, Manganelli S and Galeazzi M. **Drug retention rates and treatment discontinuation among anti-TNF-alpha agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.** *Mediators Inflamm.* 2014; **2014**:862969. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
22. Garces S, Demengeot J and Benito-Garcia E. **The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.** *Ann Rheum Dis.* 2013; **72**:1947-55. | [Article](#) | [PubMed](#)
23. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB and van Riel PL. **Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.** *Arthritis Rheum.* 1995; **38**:44-8. | [Article](#) | [PubMed](#)
24. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P and Calin A. **A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.** *J Rheumatol.* 1994; **21**:2286-91. | [PubMed](#)
25. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB and van Riel PL. **Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.** *Arthritis Rheum.* 1996; **39**:34-40. | [Article](#) | [PubMed](#)
26. Meroni PL, Valentini G, Ayala F, Cattaneo A and Valesini G. **New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis.** *Autoimmun Rev.* 2015; **14**:812-29. | [Article](#) | [PubMed](#)
27. Zisapel M, Zisman D, Madar-Balakisri N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D and Elkayam O. **Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis.** *J Rheumatol.* 2015; **42**:73-8. | [Article](#) | [PubMed](#)
28. Kvien TK, Uhlig T, Odegard S and Heiberg MS. **Epidemiological aspects of rheumatoid arthritis: the sex ratio.** *Ann N Y Acad Sci.* 2006; **1069**:212-22. | [Article](#) | [PubMed](#)
29. Bakland G and Nossent HC. **Epidemiology of spondyloarthritis: a review.** *Curr Rheumatol Rep.* 2013; **15**:351. | [Article](#) | [PubMed](#)
30. de Vries MK, Wolbink GJ, Stapel SO, de Vrieeze H, van Denderen JC, Dijkmans BA, Aarden LA and van der Horst-Bruinsma IE. **Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.** *Ann Rheum Dis.* 2007; **66**:1252-4. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
31. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore

- D, Ruiz Del Agua A, Martinez A, Aarden L, Martin-Mola E and Balsa A. **Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.** *Rheumatology (Oxford)*. 2011; **50**:1445-52. | [Article](#) | [PubMed](#)
32. Plasencia C, Pascual-Salcedo D, Garcia-Carazo S, Lojo L, Nuno L, Villalba A, Peiteado D, Arribas F, Diez J, Lopez-Casla MT, Martin-Mola E and Balsa A. **The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.** *Arthritis Res Ther*. 2013; **15**:R79. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
33. Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla G, Villalba A, Peiteado D, Diez J, Nagore D, del Agua AR, Moral R, Martin-Mola E and Balsa A. **Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.** *Ann Rheum Dis*. 2012; **71**:1955-60. | [Article](#) | [PubMed](#)
34. Anderson PJ. **Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.** *Semin Arthritis Rheum*. 2005; **34**:19-22. | [Article](#) | [PubMed](#)
35. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C and Bonfa E. **Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.** *Clin Rev Allergy Immunol*. 2010; **38**:82-9. | [Article](#) | [PubMed](#)
36. Arstikyte I, Kapleryte G, Butrimiene I and Venalis A. **Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF alpha Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.** *Biomed Res Int*. 2015; **2015**:604872. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
37. Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ and Brouwer E. **The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis.** *Clin Exp Rheumatol*. 2010; **28**:661-8. | [Article](#) | [PubMed](#)
38. Hsu L, Snodgrass BT and Armstrong AW. **Antidrug antibodies in psoriasis: a systematic review.** *Br J Dermatol*. 2014; **170**:261-73. | [Article](#) | [PubMed](#)
39. Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauferon F, Ternant D, Watier H and Goupille P. **Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases.** *Arthritis Res Ther*. 2011; **13**:R105. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
40. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sorensen H, Zeidler H, Visvanathan S, Sieper J and Braun J. **Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.** *J Rheumatol*. 2007; **34**:510-5. | [Article](#) | [PubMed](#)
41. Krzysiek R, Breban M, Ravaud P, Prejean MV, Wijdenes J, Roy C, Henry YD, Barbey C, Trappe G, Dougados M and Emilie D. **Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study.** *Arthritis Rheum*. 2009; **61**:569-76. | [Article](#) | [PubMed](#)
42. Paramarta JE and Baeten DL. **Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation.** *Arthritis Res Ther*. 2014; **16**:R160. | [Article](#) | [PubMed Abstract](#) | [PubMed FullText](#)
43. van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ and Tak PP. **Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.** *Ann Rheum Dis*. 2010; **69**:624-5. | [Article](#) | [PubMed](#)
44. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W and Rutgeerts P. **Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.** *Clin Gastroenterol Hepatol*. 2004; **2**:542-53. | [Article](#) | [PubMed](#)

Citation:

Lombardi S, Bernardoni C, Bertolucci D, Cecchetti R, Giorgio FD, Occhipinti G, Palagi A, Bertacca G, Giannelli I, Bonomi E, Friggeri M and Tartarelli G. **Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy.** *J Autoimmun Cell Response*. 2017; **4**:1.

<http://dx.doi.org/10.7243/2054-989X-4-1>